AU9617398A - Erythropoietin-mediated neurogenesis - Google Patents

Erythropoietin-mediated neurogenesis

Info

Publication number
AU9617398A
AU9617398A AU96173/98A AU9617398A AU9617398A AU 9617398 A AU9617398 A AU 9617398A AU 96173/98 A AU96173/98 A AU 96173/98A AU 9617398 A AU9617398 A AU 9617398A AU 9617398 A AU9617398 A AU 9617398A
Authority
AU
Australia
Prior art keywords
erythropoietin
neurogenesis
mediated
mediated neurogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU96173/98A
Other languages
English (en)
Inventor
S. Todd Sorokan
Samuel Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurospheres Holdings Ltd
Original Assignee
Neurospheres Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22046528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU9617398(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurospheres Holdings Ltd filed Critical Neurospheres Holdings Ltd
Publication of AU9617398A publication Critical patent/AU9617398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU96173/98A 1997-10-24 1998-10-23 Erythropoietin-mediated neurogenesis Abandoned AU9617398A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6304097P 1997-10-24 1997-10-24
US60063040 1997-10-24
PCT/CA1998/000991 WO1999021966A1 (en) 1997-10-24 1998-10-23 Erythropoietin-mediated neurogenesis

Publications (1)

Publication Number Publication Date
AU9617398A true AU9617398A (en) 1999-05-17

Family

ID=22046528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU96173/98A Abandoned AU9617398A (en) 1997-10-24 1998-10-23 Erythropoietin-mediated neurogenesis

Country Status (5)

Country Link
US (7) US6165783A (enExample)
JP (1) JP2001520878A (enExample)
AU (1) AU9617398A (enExample)
CA (1) CA2307017C (enExample)
WO (1) WO1999021966A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6610540B1 (en) * 1998-11-18 2003-08-26 California Institute Of Technology Low oxygen culturing of central nervous system progenitor cells
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7410941B1 (en) 1999-04-13 2008-08-12 The Kenneth S. Warren Institute, Inc. Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
DE19928210B4 (de) * 1999-06-19 2005-08-18 Neuroprogen Gmbh Leipzig Neuronales Zellmaterial und Verfahren zu dessen Herstellung
AU784303B2 (en) 1999-07-16 2006-03-09 Prescient Neuropharma Inc. Methods for producing and preparing cells for cell therapy
AU3499801A (en) * 2000-02-11 2001-08-20 Schepens Eye Res Inst Isolation and transplantation of retinal stem cells
CN1318084C (zh) * 2000-05-26 2007-05-30 奥索-麦克尼尔药品公司 神经保护肽
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
JP5053499B2 (ja) * 2000-06-30 2012-10-17 地方独立行政法人東京都健康長寿医療センター 脱髄疾患の予防及び治療薬
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6908902B2 (en) 2001-02-02 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
US7838292B1 (en) * 2001-03-29 2010-11-23 University Of Louisville Research Foundation, Inc. Methods for obtaining adult human olfactory progenitor cells
AU2002325712C1 (en) * 2001-08-30 2008-07-31 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
KR100505152B1 (ko) * 2001-09-10 2005-08-03 (주)가이아진 아스코르브산을 이용한 에리트로포이에틴의 생산방법
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
WO2003024471A2 (en) * 2001-09-18 2003-03-27 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
WO2003060085A2 (en) * 2002-01-14 2003-07-24 The Board Of Trustees Of The University Of Illinois Mammalian neural stem cells, compositions and uses thereof
AU2003218045A1 (en) * 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
WO2003103608A2 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
MXPA05000063A (es) * 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
WO2004011497A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
WO2004075818A2 (en) * 2003-02-26 2004-09-10 Proteosys Ag Stress specific molecular response in neurons
NZ542092A (en) * 2003-03-27 2008-04-30 Janssen Pharmaceutica Nv Use of erythropoietin (EPO) in stroke recovery wherein the EPO is formulated for administration for a particular dosage regime
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
CA2537960C (en) * 2003-09-12 2012-01-10 Stemcell Technologies Inc. Neural colony forming assay
US7546127B2 (en) * 2003-09-26 2009-06-09 Siemens Communications, Inc. System and method for centrally-hosted presence reporting
KR20070008519A (ko) * 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
EP1550715A1 (de) * 2003-12-30 2005-07-06 Bionethos Holding Gmbh Verfahren zur Regenation von Gewebe
WO2005063965A1 (de) 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
ES2392282T3 (es) * 2004-02-13 2012-12-07 Stem Cell Therapeutics Corp. Uso de la hormona luteinizante (LH) y de la gonadotropina coriónica (hCG) para la proliferación de células precursoras neurales y la neurogénesis
WO2005079250A2 (en) * 2004-02-13 2005-09-01 Cornell Research Foundation, Inc. Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
SG163588A1 (en) * 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
US7776592B2 (en) * 2005-08-31 2010-08-17 Stc.Unm Human renal stem cells
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
US20070077200A1 (en) * 2005-09-30 2007-04-05 Baker Clark R Method and system for controlled maintenance of hypoxia for therapeutic or diagnostic purposes
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US20070184034A1 (en) * 2006-02-08 2007-08-09 Cvac Systems, Inc. Combination Pressure Therapy for Treatment of Hypertension, Blood Production, and Stem Cell Therapy
US8899228B2 (en) 2006-02-08 2014-12-02 Cvac Systems, Inc. Combination pressure therapy for treatment of chronic pain
CN101495078B (zh) * 2006-02-08 2013-02-13 Cvac系统有限公司 组合压力疗法
AU2007229300B2 (en) * 2006-03-17 2013-08-01 Stem Cell Therapeutics Corp. Dosing regimes for LH or hCG and EPO for treatment of neurological disorders
JP5959795B2 (ja) * 2006-08-18 2016-08-02 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 血液脳関門送達のための物質
EP2081956B1 (en) * 2006-11-13 2013-03-20 Charité - Universitätsmedizin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
AU2008219374A1 (en) 2007-02-26 2008-09-04 Cvac Systems, Inc. Combination pressure therapy for treatment of serum lipid levels, steroid levels, and steroidogenesis
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2182980A4 (en) * 2007-07-27 2012-04-18 Armagen Technologies Inc METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
EP3103880A1 (en) 2008-02-08 2016-12-14 Ambrx, Inc. Modified leptin polypeptides and their uses
AU2009274076C1 (en) 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
US8790638B2 (en) * 2009-02-04 2014-07-29 Stemedica Cell Technologies, Inc. Compositions of stem cells and stem cell factors and methods for their use and manufacture
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
HRP20190690T1 (hr) 2009-10-09 2019-06-28 Armagen, Inc. Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2785378B1 (en) 2011-12-02 2020-05-13 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
EP2814947B1 (en) 2012-02-17 2018-11-21 Schepens Eye Research Institute Phenotype profile of human retinal progenitor cells
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
KR102056447B1 (ko) * 2018-03-16 2019-12-16 (주)메디노 신경줄기세포를 이용한 혈관형성 유도 방법
CN110713982A (zh) * 2019-11-25 2020-01-21 深圳科学之门生物工程有限公司 一种用于神经干细胞快速扩增的培养基

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0594669B9 (en) * 1991-07-08 2008-03-19 NeuroSpheres Holdings Ltd. Growth factor-responsive neural progenitor cells which can be proliferated in vitro.
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
ES2194016T5 (es) * 1992-10-28 2007-11-16 Neurospheres Holdings Ltd. Factores biologicos y celulas germinales neurales.
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
CN1141058A (zh) * 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 中枢神经系统干细胞的原位修饰和处理
EP0792350A1 (en) * 1994-11-14 1997-09-03 Neurospheres Holdings Ltd. Regulation of neural stem cell proliferation
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis

Also Published As

Publication number Publication date
CA2307017C (en) 2014-01-28
US20020098585A1 (en) 2002-07-25
US6368854B2 (en) 2002-04-09
US20060127372A1 (en) 2006-06-15
US20010039049A1 (en) 2001-11-08
US6165783A (en) 2000-12-26
WO1999021966A1 (en) 1999-05-06
JP2001520878A (ja) 2001-11-06
US6924142B2 (en) 2005-08-02
US20020094571A1 (en) 2002-07-18
US20050026136A1 (en) 2005-02-03
US20030104619A1 (en) 2003-06-05
CA2307017A1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU9617398A (en) Erythropoietin-mediated neurogenesis
AU1709299A (en) Mixer-injectors
AU9414098A (en) Ascorbyl-phosphoryl-cholesterol
AU6598798A (en) Resorcinyl-triazines
AU1027499A (en) 32P-polyphosphazene
AU5272198A (en) EMP-charge-eliminator
AU4117497A (en) Micropolarimeter
AU6998698A (en) Dioxacycloalkan-8-one
AU6185898A (en) Clavaspirins
AU4469997A (en) Heregulin-gamma
AU5391798A (en) Thiamacrolides
AU8991998A (en) Renovative pipeliner
AU5540298A (en) Rockbolts
AU6237398A (en) N-het-substituted glycerophosphoethanolamines
AU6060598A (en) Multi-hopper
AU7780498A (en) Cafetiere
AUPO975897A0 (en) Remouldable form
AUPO646297A0 (en) Braille-vision
AUPO606097A0 (en) Multi-hopper
AUPO560497A0 (en) Ezy-lid
AUPO547897A0 (en) Ready-flight
AUPO547797A0 (en) Oceancam
AUPO502797A0 (en) Weeaphone
AUPO450797A0 (en) Flexmaran
AUPO488397A0 (en) Sensacam

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase